SeouLinBioscienceCO.,LTD.
038070 | KO
Overview
Corporate Details
- ISIN(s):
- KR7038070009
- LEI:
- Country:
- South Korea
- Address:
- 경기도 성남시 분당구 삼평동 694-1 코리아바이오파크(KOREA BIO PARK) A동 4층, 성남시
- Website:
- N/A
- Sector:
- Professional, scientific and technical activities
- Industry:
- Research and experimental development on natural sciences and engineering
Description
No description available.
Unlock This Filing & Millions More
You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.
Filings
You have of free filing views remaining.
Upgrade for unlimited access.
Bulk Actions:
| Date | Filing | Language | Size | Actions | |
|---|---|---|---|---|---|
| 2025-08-14 00:00 |
Interim / Quarterly Report
반기보고서 (2025.06)
|
Korean | 1.7 MB | ||
| 2025-06-13 00:00 |
Share Issue/Capital Change
증권발행결과(자율공시)
|
Korean | 5.6 KB | ||
| 2025-06-11 00:00 |
Capital/Financing Update
주요사항보고서(전환사채권발행결정)
|
Korean | 88.9 KB | ||
| 2025-05-15 00:00 |
Quarterly Report
분기보고서 (2025.03)
|
Korean | 1.6 MB | ||
| 2025-04-09 00:00 |
Major Shareholding Notification
주식등의대량보유상황보고서(약식)
|
Korean | 64.6 KB | ||
| 2025-04-01 00:00 |
Major Shareholding Notification
임원ㆍ주요주주특정증권등소유상황보고서
|
Korean | 24.2 KB | ||
| 2025-04-01 00:00 |
Major Shareholding Notification
임원ㆍ주요주주특정증권등소유상황보고서
|
Korean | 24.2 KB | ||
| 2025-04-01 00:00 |
Major Shareholding Notification
임원ㆍ주요주주특정증권등소유상황보고서
|
Korean | 24.1 KB | ||
| 2025-03-26 00:00 |
AGM Information
정기주주총회결과
|
Korean | 25.3 KB | ||
| 2025-03-18 00:00 |
Audit Report / Information
감사보고서제출
|
Korean | 25.3 KB | ||
| 2025-03-18 00:00 |
Audit Report / Information
[첨부추가]사업보고서 (2024.12)
|
Korean | 561.6 KB | ||
| 2025-03-10 00:00 |
Earnings Release
[기재정정]매출액또는손익구조30%(대규모법인은15%)이상변동
|
Korean | 16.0 KB | ||
| 2025-03-10 00:00 |
Pre-Annual General Meeting Information
주주총회소집공고
|
Korean | 223.4 KB | ||
| 2025-03-10 00:00 |
Proxy Solicitation & Information Statement
의결권대리행사권유참고서류
|
Korean | 222.4 KB | ||
| 2025-02-20 00:00 |
Pre-Annual General Meeting Information
주주총회소집결의
|
Korean | 11.7 KB |
Automate Your Workflow. Get a real-time feed of all SeouLinBioscienceCO.,LTD. filings delivered via API.
Market Data
Market Data Not Available
Last Price
Change / %
Market Cap
N/A
Volume
Day High
Day Low
52W High
52W Low
Financials & KPIs
No data available
Unlock Full Financials for SeouLinBioscienceCO.,LTD.
This data is available as part of our premium data solutions. Contact our team for access.
Need More History? Access decades of standardized financials for SeouLinBioscienceCO.,LTD. via our API.
Insider Transactions
| Date | Insider Name | Position | Type | Shares | Value |
|---|---|---|---|---|---|
| No insider transactions recorded for this company. | |||||
Peer Companies
Company
Country
Ticker
View
Developing first-in-class radiopharmaceuticals for the diagnosis and treatment of cancer.
United States of America
RADX
United States of America
RADX
Invests in and develops novel therapeutics for cancer and rare diseases.
United States of America
RFL
United States of America
RFL
Develops ionization tech to generate rain and mitigate fog for water-scarce regions.
United States of America
RAIN
United States of America
RAIN
Develops therapies for severe and rare diseases in hematology and complement dysregulation.
United States of America
RLYB
United States of America
RLYB
An R&D firm discovering novel small molecules for out-licensing to pharma partners.
Japan
4579
Japan
4579
AI-driven biotech accelerating drug discovery for rare diseases and oncology.
United States of America
RXRX
United States of America
RXRX
A clinical-stage biotech developing novel therapies for CNS diseases and oncology.
United States of America
RLMD
United States of America
RLMD
Develops a device platform for delivering targeted therapies directly to solid tumors.
United States of America
RNXT
United States of America
RNXT
Develops precision oncology drugs using a CRISPR platform for cancers with genomic instabilities.
United States of America
RPTX
United States of America
RPTX
Clinical-stage biotech developing oncolytic immunotherapies to treat a broad range of cancers.
United States of America
REPL
United States of America
REPL